Advertisement

Annals of Surgical Oncology

, Volume 19, Issue 12, pp 3706–3712 | Cite as

Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal Cancer

  • Johannes Betge
  • Peter Kornprat
  • Marion J. Pollheimer
  • Richard A. Lindtner
  • Andrea Schlemmer
  • Peter Rehak
  • Michael Vieth
  • Cord LangnerEmail author
Colorectal Cancer

Abstract

Background

In colorectal cancer, the morphology of the invasive tumor margin may reflect aggressiveness of tumor growth, thus providing important prognostic information. The tumor growth pattern according to Jass and the extent of tumor budding were analyzed in patients with American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) stage II disease.

Methods

Tumors of 120 randomly selected patients with AJCC/UICC stage II disease were retrospectively reviewed for tumor growth pattern (expanding vs. infiltrating) and the extent of tumor budding, with high-grade budding reflecting presence of 10 or more budding foci scattered at the invasive tumor margin. Progression-free and cancer-specific survivals were determined by the Kaplan–Meier method. For multivariable analysis, Cox’s proportional hazards regression models were performed.

Results

The infiltrating growth pattern was significantly associated with histological subtype and lymphovascular invasion, while high-grade budding was significantly associated with tumor grade and lymphovascular invasion. High-grade budding, but not the infiltrating growth pattern, was significantly associated with outcome in univariable analysis. Cox’s proportional hazards regression models proved tumor budding to be an independent predictor of disease progression (hazard ratio 3.91, 95 % confidence interval 1.3–11.77; P = 0.02) and cancer-related death (hazard ratio 5.90, 95 % confidence interval 1.62–21.51; P = 0.007). The combination of infiltrating growth pattern and high-grade budding did not have a stronger prognostic significance than tumor budding alone.

Conclusions

Tumor budding independently predicted patient outcome in patients with AJCC/UICC stage II colorectal cancer and may therefore be used for accurate prognostication, patient counseling, and design of clinical trials by using integrated multimodal therapy.

Keywords

Rectal Cancer Invasive Margin Infiltrate Growth Pattern Predict Disease Progression Tumor Growth Pattern 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

No conflict of interest and no financial disclosures from any author.

References

  1. 1.
    Compton CC. Optimal pathologic staging: defining stage II disease. Clin Cancer Res. 2007;13:6862–70.CrossRefGoogle Scholar
  2. 2.
    McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999;79:191–203.CrossRefPubMedGoogle Scholar
  3. 3.
    Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res. 2006;12:1184–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Jass JR, Atkin WS, Cuzick J, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology. 1986;10:437–59.CrossRefPubMedGoogle Scholar
  5. 5.
    Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet. 1987;1:1303–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour “budding” as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Prall F. Tumour budding in colorectal carcinoma. Histopathology. 2007;50:151–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Sobin L, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th edition. West Sussex: Wiley-Blackwell; 2010.Google Scholar
  11. 11.
    Hamilton SR, Bosman FT, Boffetta P, et al. Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. World Health Organization classification of tumours of the digestive system. Lyon: IARC; 2010. p. 131–81.Google Scholar
  12. 12.
    Kanazawa H, Mitomi H, Nishiyama Y, et al. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2008;10:41–7.PubMedGoogle Scholar
  13. 13.
    Zlobec I, Terracciano L, Tornillo L, et al. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut. 2008;57:1413–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Ueno H, Price AB, Wilkinson KH, Jass JR, Mochizuki H, Talbot IC. A new prognostic staging system for rectal cancer. Ann Surg. 2004;240:832–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum. 2003;46:1400–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Choi DH, Sohn DK, Chang HJ, Lim SB, Choi HS, Jeong SY. Indications for subsequent surgery after endoscopic resection of submucosally invasive colorectal carcinomas: a prospective cohort study. Dis Colon Rectum. 2009;52:438–45.CrossRefPubMedGoogle Scholar
  17. 17.
    Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008;28:1831–6.PubMedGoogle Scholar
  18. 18.
    Shepherd NA, Saraga EP, Love SB, Jass JR. Prognostic factors in colonic cancer. Histopathology. 1989;14:613–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Cianchi F, Messerini L, Palomba A, et al. Character of the invasive margin in colorectal cancer: does it improve prognostic information of Dukes staging? Dis Colon Rectum. 1997;40:1170–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Roncucci L, Fante R, Losi L, et al. Survival for colon and rectal cancer in a population-based cancer registry. Eur J Cancer. 1996;32A:295–302.CrossRefPubMedGoogle Scholar
  21. 21.
    Ueno H, Jones A, Jass JR, Talbot IC. Clinicopathological significance of the “keloid-like” collagen and myxoid stroma in advanced rectal cancer. Histopathology. 2002;40:327–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Cianchi F, Messerini L, Comin CE, et al. Pathologic determinants of survival after resection of T3N0 (stage IIA) colorectal cancer: proposal for a new prognostic model. Dis Colon Rectum. 2007;50:1332–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Zlobec I, Baker K, Minoo P, Hayashi S, Terracciano L, Lugli A. Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups. Cancer. 2009;115:4021–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum. 2008;51:568–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum. 2003;46:1054–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33:134–41.CrossRefPubMedGoogle Scholar
  27. 27.
    Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology. 2005;47:17–24.CrossRefPubMedGoogle Scholar
  28. 28.
    Shinto E, Jass JR, Tsuda H, et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum. 2006;49:1422–30.CrossRefPubMedGoogle Scholar
  29. 29.
    Yoshida K, Yoshimatsu K, Otani T, Yokomizo H, Ogawa K. The depth of tumor invasion beyond the outer border of the muscularis propria as a prognostic factor for T3 rectal/rectosigmoid cancer. Anticancer Res. 2008;28:1773–8.PubMedGoogle Scholar
  30. 30.
    Okuyama T, Oya M, Ishikawa H. Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol. 2003;83:42–7.CrossRefPubMedGoogle Scholar
  31. 31.
    De Quay N, Cerottini JP, Albe X, Saraga E, Givel JC, Caplin S. Prognosis in Duke’s B colorectal carcinoma: the Jass classification revisited. Eur J Surg. 1999;165:588–92.CrossRefPubMedGoogle Scholar
  32. 32.
    Sato H, Maeda K, Sugihara K, et al. High-risk stage II colon cancer after curative resection. J Surg Oncol. 2011;104:45–52.CrossRefPubMedGoogle Scholar
  33. 33.
    Vieth M, Quirke P, Lambert R, von Karsa L, Risio M. Annex to Quirke et al. Quality assurance in pathology in colorectal cancer screening and diagnosis: annotations of colorectal lesions. Virchows Arch. 2011;458:21–30.CrossRefPubMedGoogle Scholar
  34. 34.
    Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol. 2003;16:376–88.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Johannes Betge
    • 1
  • Peter Kornprat
    • 2
  • Marion J. Pollheimer
    • 1
  • Richard A. Lindtner
    • 1
  • Andrea Schlemmer
    • 3
  • Peter Rehak
    • 4
  • Michael Vieth
    • 5
  • Cord Langner
    • 1
    Email author
  1. 1.Institute of PathologyMedical University of GrazGrazAustria
  2. 2.Division of General Surgery, Department of SurgeryMedical University of GrazGrazAustria
  3. 3.Institute for Medical Informatics, Statistics and DocumentationMedical University of GrazGrazAustria
  4. 4.Research Unit for Biomedical Engineering and Computing, Department of SurgeryMedical University of GrazGrazAustria
  5. 5.Institute of PathologyKlinikum BayreuthBayreuthGermany

Personalised recommendations